Neyrokson 100 mg / ml, 45ml 1's oral solution in the vial with a syringe dosed
- $45.00
The instruction for medical use
of NEYROKSON medicine
the Trade name
Neurokson
Mezhdunarodnoye the unlicensed
name Tsitikolin (citicoline)
the Dosage form
Solution for oral administration, 100 mg/ml
Structure
of 1 ml of drug contains
active agent: a tsitikolina of sodium (in terms of tsitikolin) – 104.50 mg (100.00 mg)
excipients: methylparahydroxybenzoate (E 218), propilparagidroksibenzoat (E 216), potassium sorbate, glycerin, sorbite, glitserinformal, sodium citrate, sodium saccharin, citric acid monohydrate, water
the liquid purified the Description Colourless or with a yellow shade with a specific smell. Opalescence
Pharmacotherapeutic group
of Psikhoanaleptiki is allowed. Psychostimulants and nootropa. Other psychogogic and nootropic means. Tsitikolin.
The ATX N06B X06 code
the Pharmacological
Pharmacokinetics Tsitikolin properties is well soaked up at oral administration. After administration of drug the substantial increase of level of sincalines in blood plasma is observed. At oral administration, drug is almost completely soaked up. Researches showed that bioavailability at oral and parenteral ways of introduction are almost identical.
Drug is metabolized in intestines and a liver with formation of sincaline and cytidine. After introduction tsitikolin it is acquired by brain tissues, at the same time sincalines affect phospholipids, cytidine - on cytidine nucleoids and nucleic acids. Tsitikolin quickly reaches tissues of a brain and is actively built in cell membranes, cytoplasm and mitochondrions, activating activity of phospholipids.
Only the insignificant quantity of the entered dose is removed with urine and a stake (less than 3%). About 12% of the entered dose are removed through airways. Removal of drug with urine and through airways has two phases: the first phase – fast removal (with urine – for the first 36 hours, through airways – for the first 15 hours), the second phase – slow release. The main part of a dose of drug is involved in metabolism processes.
The pharmacodynamics
Tsitikolin stimulates biosynthesis of structural phospholipids in a membrane of neurons that promotes improvement of functions of membranes, including functioning of ion-exchange pumps and neuroceptors. Thanks to the stabilizing action on a membrane tsitikolin has antiedematous properties therefore reduces wet brain. Tsitikolin oppresses activity of some phospholipases, interferes with residual release of free radicals, prevents damage of membrane systems and provides preservation of a protective antioxidant system.
Tsitikolin reduces the volume of the damaged fabric, preventing death of cells, affecting apoptosis mechanisms, and improves cholinergic transfer. Tsitikolin also has preventive neurotyre-tread effect in focal strokes of a brain.
Tsitikolin promotes fast functional rehabilitation of patients in acute disorders of cerebral circulation, reducing ischemic defeat of tissues of brain that is confirmed by results of X-ray inspections.
In craniocereberal injuries tsitikolin reduces duration of the recovery period and reduces intensity of a posttraumatic syndrome.
Tsitikolin promotes increase in level of brain activity, reduces amnesia level, improves a state at cognitive, sensitive and motor disturbances which are observed in brain ischemia.
Indications
- a sharp phase of disturbances of cerebral circulation and treatment of complications and consequences of disturbances of cerebral circulation.
- craniocereberal injury and its consequences.
- the neurologic disturbances (cognitive, sensitive, motor) caused by cerebral pathology of degenerative and vascular genesis.
The route of administration and doses
Apply inside. The recommended dose for adults makes from 500 mg (5 ml) to 2000 mg (20 ml) the day divided into 2-3 receptions. Accept irrespective of consumption of food. The drug which is previously mixed with a small amount of water is accepted by means of the dosing syringe. It is necessary to wash the dosing syringe (pipette doser) with water after each use.
Doses of drug and the term of treatment depend on weight of damage of a brain and are established by the doctor individually.
Patients of advanced age do not demand dose adjustment.
Side effects
Side reactions arise very seldom (& lt, 1/10000), including isolated cases
- hallucinations, excitement, a tremor, feeling of heat
- arterial hypertension, arterial hypotension, tachycardia
- a severe headache, dizziness
- dispnoe
- nausea, vomiting, diarrhea
- a fever, hypostasis, allergic reactions, including rash, a small tortoiseshell, a purpura, an itching, angionevrogichesky hypostasis, an acute anaphylaxis
of the Contraindication
- hypersensitivity to drug components,
- the raised tone of parasympathetic nervous system.
Medicinal interactions
Tsitikolin enhances effect of a levodopa. It is not necessary to appoint along with the medicines containing Meclofenoxatum.
Patients with an inherited disorder of tolerance to fructose should not accept special instructions Neurokson, solution for oral administration, because of presence of sorbite in it. Metilparagidroksibenzoat and propilparagidroksibenzoat, contained in composition of drug, can cause allergic reactions (usually slowed down type).
Use during pregnancy and a lactation.
There are not enough data on Neurokson's use by pregnant women. Data on excretion of a tsitikolin in breast milk and its action on a fruit are not known. Therefore during pregnancy or feeding a breast drug is appointed only when the expected advantage for mother exceeds potential risk for the fruit/child.
Use in pediatrics
is Not enough data on Neurokson's use to children. Drug is used in urgent cases when the expected advantage of use exceeds potential risk.
Features of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms
In some cases some side reactions from the central nervous system can affect ability to run motor transport and to work with difficult mechanisms.
Overdose
Cases of overdose are not described.
In case of emergence, symptoms of overdose are shown by strengthening of side effect of drug.
Treatment: symptomatic.
The form of release and packing
On 45 ml of drug spill in bottles glass, corked by covers with control of the first opening. On bottles paste the label.
On 1 bottle together with the instruction for medical use in the state and Russian languages and to the syringes the doser (the pipette dosing) put in a pack.
To Store storage conditions in original packing, at a temperature not above 30 °C. Not to freeze and not to cool! In the course of storage the emergence of the easy opalescence disappearing when keeping drug at the room temperature is possible (≈ 20 °C).
To store out of children's reach!
A period of storage
2 years
not to apply after an expiration date
Prescription status
According to the prescription
JSC Galichpharm Producer, Ukraine, 79024, Lviv, Opryshkovskaya St., 6/8.
Owner of the registration certificate
of JSC Galichpharm, Ukraine.
The address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products: Representative office of Arterium corporation in the Republic of KazahstanRespublika Kazakhstan, 050060, Almaty, Al-Farabi Avenue 97, 3 entrance, office 54 Ph. / fax: 8 (727) 315-82-09, 8 (727) 315-82-10, E-mail: Almaty@arterium.ua
of NEYROKSON medicine
the Trade name
Neurokson
Mezhdunarodnoye the unlicensed
name Tsitikolin (citicoline)
the Dosage form
Solution for oral administration, 100 mg/ml
Structure
of 1 ml of drug contains
active agent: a tsitikolina of sodium (in terms of tsitikolin) – 104.50 mg (100.00 mg)
excipients: methylparahydroxybenzoate (E 218), propilparagidroksibenzoat (E 216), potassium sorbate, glycerin, sorbite, glitserinformal, sodium citrate, sodium saccharin, citric acid monohydrate, water
the liquid purified the Description Colourless or with a yellow shade with a specific smell. Opalescence
Pharmacotherapeutic group
of Psikhoanaleptiki is allowed. Psychostimulants and nootropa. Other psychogogic and nootropic means. Tsitikolin.
The ATX N06B X06 code
the Pharmacological
Pharmacokinetics Tsitikolin properties is well soaked up at oral administration. After administration of drug the substantial increase of level of sincalines in blood plasma is observed. At oral administration, drug is almost completely soaked up. Researches showed that bioavailability at oral and parenteral ways of introduction are almost identical.
Drug is metabolized in intestines and a liver with formation of sincaline and cytidine. After introduction tsitikolin it is acquired by brain tissues, at the same time sincalines affect phospholipids, cytidine - on cytidine nucleoids and nucleic acids. Tsitikolin quickly reaches tissues of a brain and is actively built in cell membranes, cytoplasm and mitochondrions, activating activity of phospholipids.
Only the insignificant quantity of the entered dose is removed with urine and a stake (less than 3%). About 12% of the entered dose are removed through airways. Removal of drug with urine and through airways has two phases: the first phase – fast removal (with urine – for the first 36 hours, through airways – for the first 15 hours), the second phase – slow release. The main part of a dose of drug is involved in metabolism processes.
The pharmacodynamics
Tsitikolin stimulates biosynthesis of structural phospholipids in a membrane of neurons that promotes improvement of functions of membranes, including functioning of ion-exchange pumps and neuroceptors. Thanks to the stabilizing action on a membrane tsitikolin has antiedematous properties therefore reduces wet brain. Tsitikolin oppresses activity of some phospholipases, interferes with residual release of free radicals, prevents damage of membrane systems and provides preservation of a protective antioxidant system.
Tsitikolin reduces the volume of the damaged fabric, preventing death of cells, affecting apoptosis mechanisms, and improves cholinergic transfer. Tsitikolin also has preventive neurotyre-tread effect in focal strokes of a brain.
Tsitikolin promotes fast functional rehabilitation of patients in acute disorders of cerebral circulation, reducing ischemic defeat of tissues of brain that is confirmed by results of X-ray inspections.
In craniocereberal injuries tsitikolin reduces duration of the recovery period and reduces intensity of a posttraumatic syndrome.
Tsitikolin promotes increase in level of brain activity, reduces amnesia level, improves a state at cognitive, sensitive and motor disturbances which are observed in brain ischemia.
Indications
- a sharp phase of disturbances of cerebral circulation and treatment of complications and consequences of disturbances of cerebral circulation.
- craniocereberal injury and its consequences.
- the neurologic disturbances (cognitive, sensitive, motor) caused by cerebral pathology of degenerative and vascular genesis.
The route of administration and doses
Apply inside. The recommended dose for adults makes from 500 mg (5 ml) to 2000 mg (20 ml) the day divided into 2-3 receptions. Accept irrespective of consumption of food. The drug which is previously mixed with a small amount of water is accepted by means of the dosing syringe. It is necessary to wash the dosing syringe (pipette doser) with water after each use.
Doses of drug and the term of treatment depend on weight of damage of a brain and are established by the doctor individually.
Patients of advanced age do not demand dose adjustment.
Side effects
Side reactions arise very seldom (& lt, 1/10000), including isolated cases
- hallucinations, excitement, a tremor, feeling of heat
- arterial hypertension, arterial hypotension, tachycardia
- a severe headache, dizziness
- dispnoe
- nausea, vomiting, diarrhea
- a fever, hypostasis, allergic reactions, including rash, a small tortoiseshell, a purpura, an itching, angionevrogichesky hypostasis, an acute anaphylaxis
of the Contraindication
- hypersensitivity to drug components,
- the raised tone of parasympathetic nervous system.
Medicinal interactions
Tsitikolin enhances effect of a levodopa. It is not necessary to appoint along with the medicines containing Meclofenoxatum.
Patients with an inherited disorder of tolerance to fructose should not accept special instructions Neurokson, solution for oral administration, because of presence of sorbite in it. Metilparagidroksibenzoat and propilparagidroksibenzoat, contained in composition of drug, can cause allergic reactions (usually slowed down type).
Use during pregnancy and a lactation.
There are not enough data on Neurokson's use by pregnant women. Data on excretion of a tsitikolin in breast milk and its action on a fruit are not known. Therefore during pregnancy or feeding a breast drug is appointed only when the expected advantage for mother exceeds potential risk for the fruit/child.
Use in pediatrics
is Not enough data on Neurokson's use to children. Drug is used in urgent cases when the expected advantage of use exceeds potential risk.
Features of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms
In some cases some side reactions from the central nervous system can affect ability to run motor transport and to work with difficult mechanisms.
Overdose
Cases of overdose are not described.
In case of emergence, symptoms of overdose are shown by strengthening of side effect of drug.
Treatment: symptomatic.
The form of release and packing
On 45 ml of drug spill in bottles glass, corked by covers with control of the first opening. On bottles paste the label.
On 1 bottle together with the instruction for medical use in the state and Russian languages and to the syringes the doser (the pipette dosing) put in a pack.
To Store storage conditions in original packing, at a temperature not above 30 °C. Not to freeze and not to cool! In the course of storage the emergence of the easy opalescence disappearing when keeping drug at the room temperature is possible (≈ 20 °C).
To store out of children's reach!
A period of storage
2 years
not to apply after an expiration date
Prescription status
According to the prescription
JSC Galichpharm Producer, Ukraine, 79024, Lviv, Opryshkovskaya St., 6/8.
Owner of the registration certificate
of JSC Galichpharm, Ukraine.
The address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products: Representative office of Arterium corporation in the Republic of KazahstanRespublika Kazakhstan, 050060, Almaty, Al-Farabi Avenue 97, 3 entrance, office 54 Ph. / fax: 8 (727) 315-82-09, 8 (727) 315-82-10, E-mail: Almaty@arterium.ua
Related Products
